Compare OSW & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | WVE |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Bahamas | Singapore |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2019 | 2015 |
| Metric | OSW | WVE |
|---|---|---|
| Price | $22.26 | $15.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $25.00 | ★ $30.44 |
| AVG Volume (30 Days) | 1.9M | ★ 2.8M |
| Earning Date | 05-21-2026 | 05-29-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $961,001,000.00 | $3,704,000.00 |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $7.99 | $15.93 |
| P/E Ratio | $31.62 | ★ N/A |
| Revenue Growth | 7.37 | ★ 149.43 |
| 52 Week Low | $14.21 | $5.28 |
| 52 Week High | $23.54 | $21.73 |
| Indicator | OSW | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 66.35 |
| Support Level | $20.74 | $15.23 |
| Resistance Level | $22.93 | $18.50 |
| Average True Range (ATR) | 0.99 | 0.69 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 58.97 | 94.93 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.